A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | organism | pre-condition | term | drug | increased/decreased/neutral | phenotype | compared to | negation | curation error? | comment | |||||||||||||
2 | 655384784 | CG | Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. | person | acute coronary artery syndrome | acute coronary syndrome (mesh:68054058) | beta blockers | increased | rehospitalization | GG | |||||||||||||
3 | 655387011 | GT | Patients with the CG genotype and breast cancer who are treated with cyclophosphamide may have longer disease-free progression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance of disease-free progression. | person | breast cancer | cyclophosphamide | increased | disease-free progression | TT | genotype mismatch | |||||||||||||
4 | 655385221 | CG | Patients with the CG genotype and diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype. | person | diabetes | muraglitazar | increased | edema | CC | ||||||||||||||
5 | 655385095 | CG | Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation. | person | HIV | ritonavir | decreased | triglyceride elevation | CC | ||||||||||||||
6 | 655385301 | CG | Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have symptom improvement as compared to patients with the GG genotype. | person | rheumatoid arthritis | methotrexate | decreased | symptom improvement | GG | ||||||||||||||
7 | 655384765 | CG | Patients with the CG genotype and rs1801252A who are treated with verapamil: 1)may have an increased risk for treatment failure as compared to patients with the GG genotype 2) may have an increased risk for adverse events as compared to patients with the GG genotype. | person | rs1891252 | verapamil | increased | treatment failure, adverse events | GG | rsid error | |||||||||||||
8 | 655384985 | CG | Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment. | person | schizophrenia | olanzapine | decreased | extreme weight gain | GG | ||||||||||||||
9 | 655385100 | CG | Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone. | person | diabetes type 2 | rosiglitazone | decreased | fasting plasma glucose, 2-hour postprandial glucose, and HbA1c | CC | ||||||||||||||
10 | 655385676 | CG | Patients with the CG genotype who are treated with antipsychotics may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. | person | antipsychotics | antipsychotics | increased | metabolic syndrome | GG | ||||||||||||||
11 | 655385031 | CG | Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype. | person | warfarin | decreased | dose | GG | |||||||||||||||
12 | 655384779 | CG | Patients with the CG genotype: 1) may have intermediate metabolism of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype. | person | thiopurines | increased | toxicity | CC | |||||||||||||||
13 | 655384973 | CT | Patients with the CT genotype were not studied. | no statement to convert | |||||||||||||||||||
14 | 655384706 | CT | Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone. | person | high risk of diabetes type 2 | troglitazone | increased | beta cell function | TT | beta call function | |||||||||||||
15 | 655384997 | CT | Patients with the CT genotype and bipolar disorder who are treated with lithium may be more likely to have a reduction in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | person | bipolar disorder | lithium | decreased | symptoms | TT | ||||||||||||||
16 | 655387016 | CT | Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. | person | breast cancer | cyclophophamide | decreased | disease free survival | CC | yes | |||||||||||||
17 | 655386591 | CT | Patients with the CT genotype and cancer who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the TT genotype. | person | cancer | cisplatin | increased | hearing loss | TT | ||||||||||||||
18 | 613979405 | CT | Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. | person | cluster headache | triptans | decreased | pain, frequency | CC | ||||||||||||||
19 | 655385213 | CT | Patients with the CT genotype and diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar. | person | diabetes type 2 | muraglitazar | decreased | edema | CC | ||||||||||||||
20 | 655385127 | CT | Patients with the CT genotype and erectile dysfunction who are treated with sildenafilthan may be less likely to have positive erectile response as compared to patients with the TT genotype. | person | erectile dysfunction | sildenafilthan | decreased | positive erectile response | TT | ||||||||||||||
21 | 655384864 | CT | Patients with the CT genotype and major depression who are treated with fluvoxamine, paroxetine, or milnacipran may be less likely to respond as compared to patients with the CC genotype. | person | major depression | fluvoxamine or paroxetine or milnacipran | decreased | response | CC | ||||||||||||||
22 | 655387944 | CT | Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype. | person | precursor cell lymphoblastic leukemia-lymphoma | methotrexate | increased | GI toxicity | CC | ||||||||||||||
23 | |||||||||||||||||||||||
24 | |||||||||||||||||||||||
25 | |||||||||||||||||||||||
26 | |||||||||||||||||||||||
27 | |||||||||||||||||||||||
28 | |||||||||||||||||||||||
29 | |||||||||||||||||||||||
30 | |||||||||||||||||||||||
31 | |||||||||||||||||||||||
32 | |||||||||||||||||||||||
33 | |||||||||||||||||||||||
34 | |||||||||||||||||||||||
35 | |||||||||||||||||||||||
36 | |||||||||||||||||||||||
37 | |||||||||||||||||||||||
38 | |||||||||||||||||||||||
39 | |||||||||||||||||||||||
40 | |||||||||||||||||||||||
41 | |||||||||||||||||||||||
42 | |||||||||||||||||||||||
43 | |||||||||||||||||||||||
44 | |||||||||||||||||||||||
45 | |||||||||||||||||||||||
46 | |||||||||||||||||||||||
47 | |||||||||||||||||||||||
48 | |||||||||||||||||||||||
49 | |||||||||||||||||||||||
50 | |||||||||||||||||||||||
51 | |||||||||||||||||||||||
52 | |||||||||||||||||||||||
53 | |||||||||||||||||||||||
54 | |||||||||||||||||||||||
55 | |||||||||||||||||||||||
56 | |||||||||||||||||||||||
57 | |||||||||||||||||||||||
58 | |||||||||||||||||||||||
59 | |||||||||||||||||||||||
60 | |||||||||||||||||||||||
61 | |||||||||||||||||||||||
62 | |||||||||||||||||||||||
63 | |||||||||||||||||||||||
64 | |||||||||||||||||||||||
65 | |||||||||||||||||||||||
66 | |||||||||||||||||||||||
67 | |||||||||||||||||||||||
68 | |||||||||||||||||||||||
69 | |||||||||||||||||||||||
70 | |||||||||||||||||||||||
71 | |||||||||||||||||||||||
72 | |||||||||||||||||||||||
73 | |||||||||||||||||||||||
74 | |||||||||||||||||||||||
75 | |||||||||||||||||||||||
76 | |||||||||||||||||||||||
77 | |||||||||||||||||||||||
78 | |||||||||||||||||||||||
79 | |||||||||||||||||||||||
80 | |||||||||||||||||||||||
81 | |||||||||||||||||||||||
82 | |||||||||||||||||||||||
83 | |||||||||||||||||||||||
84 | |||||||||||||||||||||||
85 | |||||||||||||||||||||||
86 | |||||||||||||||||||||||
87 | |||||||||||||||||||||||
88 | |||||||||||||||||||||||
89 | |||||||||||||||||||||||
90 | |||||||||||||||||||||||
91 | |||||||||||||||||||||||
92 | |||||||||||||||||||||||
93 | |||||||||||||||||||||||
94 | |||||||||||||||||||||||
95 | |||||||||||||||||||||||
96 | |||||||||||||||||||||||
97 | |||||||||||||||||||||||
98 | |||||||||||||||||||||||
99 | |||||||||||||||||||||||
100 |